Complete Guide to Wegovy vs Mounjaro Treatment Options
Understanding the Key Differences When Changing From Wegovy to Mounjaro
When changing from Wegovy to Mounjaro, the fundamental difference lies in their mechanisms of action. Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics your body's natural incretin hormone to promote satiety and reduce appetite. Mounjaro uses tirzepatide, a dual agonist targeting both GIP and GLP-1 receptors, offering a different approach to weight management through enhanced glucose control and appetite regulation.
The decision between these prescription-only medicines often comes down to individual response, tolerability, and clinical guidance from your prescriber. Wegovy follows a structured 5-dose escalation protocol over 16 weeks, reaching maintenance at 2.4mg weekly, whilst Mounjaro offers 6 dosing options from 2.5mg to 15mg with different titration schedules. Both require careful monitoring and should be used alongside a reduced-calorie diet and increased physical activity for optimal results.
Comprehensive Pricing Comparison for Wegovy vs Mounjaro Options
EverydayMeds offers transparent pricing for both treatments, with Wegovy single pens starting at £79.99 for the 0.25mg starter dose after applying discount code FIRST40 at checkout. Our Wegovy range includes the 0.5mg pen at £94.99, 1mg at £99.99, 1.7mg at £139.99, and the 2.4mg maintenance dose at £209.99. Bundle options provide convenience with our Intro Duo (0.25mg & 0.5mg) at £169.99 and Progress Trio (0.5mg, 1mg & 1.7mg) at £369.99 for seamless dose progression.
When considering changing from Wegovy to Mounjaro, pricing structures differ due to varying dose requirements and treatment protocols. Returning customers benefit from our DOSE25 discount code applied at checkout, whilst our Ultimate Stability Trio offers three months of 2.4mg maintenance supply for £649.99. All prices include prescriber consultation, clinical assessment, and next-day temperature-controlled delivery through our GPhC-registered pharmacy (#9012878).
Clinical Evidence Supporting Wegovy vs Mounjaro Treatment Decisions
Wegovy's efficacy is demonstrated through the landmark STEP clinical trial programme, with STEP 1 showing patients achieved approximately 15% average weight loss at 68 weeks when combined with lifestyle interventions (Wilding et al., NEJM, 2021). The STEP 2 trial specifically evaluated semaglutide in patients with type 2 diabetes, whilst STEP 5 confirmed sustained weight management benefits over two years.
When changing from Wegovy to Mounjaro, it's important to note that direct head-to-head comparisons aren't available due to different trial designs and patient populations. Both treatments have demonstrated significant weight management benefits in their respective clinical programmes, though individual responses may vary based on medical history, concurrent medications, and metabolic factors that your prescriber will evaluate during consultation.
How Wegovy Works for Weight Management When Changing From Other Treatments
Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics the action of incretin hormones naturally produced in your intestines after eating. This mechanism promotes feelings of fullness and satiety, helping reduce overall caloric intake by working on brain appetite centres. The medication slows gastric emptying, meaning food stays in your stomach longer, contributing to prolonged satisfaction after meals. GLP-1 receptors are found throughout the body, including the brain, pancreas, and digestive system, explaining semaglutide's comprehensive effects on appetite regulation. When considering changing from Wegovy to Mounjaro or vice versa, understanding these mechanisms helps inform treatment decisions with your healthcare provider.
Streamlined Ordering Process for Both Wegovy and Mounjaro Treatments
Our efficient ordering system accommodates patients changing from Wegovy to Mounjaro through a comprehensive 3-minute online clinical assessment covering medical history, current medications, and treatment goals. Prescriber review typically takes 3 working days, with express 24-hour options available for urgent requirements. Once approved, your medication is dispatched via next-day delivery using specialised cold-chain logistics to maintain temperature integrity throughout transit. Our GPhC-registered pharmacy team (#9012878) coordinates directly with prescribers to ensure seamless transitions between treatments. All orders include detailed injection guidance, storage instructions, and access to ongoing clinical support for questions about dose escalation or side effect management.
Storage and Practical Considerations When Changing Between Weight Management Treatments
Wegovy offers superior storage flexibility compared to Mounjaro, maintaining stability for up to 6 weeks at room temperature below 30°C once removed from refrigeration, versus Mounjaro's 21-day room temperature limit. The FlexTouch pen design provides precise dose delivery with clear dose counter windows and ergonomic handling for weekly self-administration. Wegovy requires mandatory dose escalation starting at 0.25mg for weeks 1-4, progressing through 0.5mg, 1mg, and 1.7mg stages before reaching 2.4mg maintenance dosing. Storage at 2-8°C in original packaging protects the medication from light exposure, whilst the extended room temperature stability makes Wegovy particularly suitable for travel or temporary storage situations. When changing from Wegovy to Mounjaro, your prescriber will provide specific guidance on washout periods and transition protocols.
Unique Considerations for Treatment Switching and Dual-Action Mechanisms
Changing from Wegovy to Mounjaro represents a shift from single GLP-1 agonism to dual GIP/GLP-1 receptor targeting, potentially offering different metabolic benefits for individuals who haven't achieved desired outcomes with semaglutide alone. The transition requires careful medical supervision due to different pharmacokinetic profiles and potential for varying side effect patterns. Some patients find Mounjaro's dual mechanism provides enhanced glucose control alongside weight management, particularly relevant for those with prediabetes or metabolic syndrome.
Alternatively, patients may prefer Wegovy's well-established safety profile and convenient storage characteristics, especially for those with active lifestyles requiring travel flexibility. The decision often depends on individual response patterns, insurance considerations, and specific metabolic goals discussed during prescriber consultation. Both treatments require commitment to long-term lifestyle modifications, as clinical evidence shows weight regain when treatment is discontinued without sustained behavioural changes.
Making Your Treatment Choice with Expert Clinical Support
EverydayMeds provides both Wegovy and Mounjaro through our comprehensive weight management programme, ensuring you have access to expert guidance when changing from Wegovy to Mounjaro or comparing initial treatment options. Our clinical team evaluates individual factors including medical history, previous treatment responses, lifestyle considerations, and specific weight management goals to recommend the most appropriate option. New customers can apply discount code FIRST40 at checkout, whilst returning patients use DOSE25 for continued savings on their chosen treatment. Visit our weight loss collection at https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and consultation process. Both treatments represent significant advances in prescription weight management, and our experienced prescribers help ensure you select the option most aligned with your health objectives and circumstances.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
